GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Long-Term Capital Lease Obligation

Gala Pharmaceutical (Gala Pharmaceutical) Long-Term Capital Lease Obligation : $0.00 Mil (As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Long-Term Capital Lease Obligation?

Gala Pharmaceutical's Long-Term Capital Lease Obligation for the quarter that ended in May. 2019 was $0.00 Mil.

Gala Pharmaceutical Long-Term Capital Lease Obligation Historical Data

The historical data trend for Gala Pharmaceutical's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Long-Term Capital Lease Obligation Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial - - - - -

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gala Pharmaceutical  (OTCPK:GLPH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Gala Pharmaceutical Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
LSE:PYC PRTX PPCB BTHE TSXV:IBT XCNQ:DOSE TSXV:APC RSPI XCNQ:LILY OBMP ASX:MEB XSAT:CLINE B AMBS WAR:RDG ASX:ACL TNTY TSXV:MFS VODG GOVX ASX:RAC
Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Website
https://www.galapharmaceuticals.com
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.